Aims: 1-Compare regional LV LS between the 3 types of CA, 2 -Determine if they correlate to amyloid deposits; 3 -Determine the prognostic value of LV LS.
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Role of 99mTc-HMDP scintigraphy in the diagnosis and follow up of cardiac amyloidosis
Arnault Galat (1), Jean Rosso (2), Aziz Guellich (1), Stephane Rappeneau Background: Accuracy of 99mTc-HMDP scintigraphy (sHMDP) to diagnose cardiac amyloidosis (CA) and to discriminate between the different etiologies i.e hereditary TTR amyloidosis (hTTR), senile amyloidosis (wt-TTR) and light chain amyloidosis (AL) are unknown.
Methods: 122 patients referred for suspected CA were prospectively studied with sHMDP. HMDP fixation was evaluated by a visual score (0 up to 3). Heart-to-whole-body (H/WB) and heart-to-skull (H/S) ratio were calculated on planar images. Diagnosis of amyloidosis was biopsy proven for all AL. Diagnosis of CA for hTTR and wt-TTR was established by an experts consensus based on echocardiography, cardiac MRI (cardiac wall thickness ≥12mm), genetic testing and biopsy whenever ethically possible.
Results:
The mean age was 69 (59; 78), 71% were men; of whom, 14 (11%) were considered having AL, 34 (28%) hTTR, 21 (17%) wt-TTR and 53 (43%) had cardiac hypertrophy from other causes. Of the 61 (50%) patients with CA, 46 (75%) had a HMDP visual scoring ≥1; of whom 1/14 (7%) had AL, 24/26 (92%) hTTR and 21/21 (100%) wt-TTR.
Cardiac HMPD uptake was absent among all patients without CA (n=61). Visual score was stronger in TTR-CA versus AL-CA (p<0.0001). A visual score ≥2 to diagnose TTR-CA had a predictive positive value of 100%. Among CA, H/WB and H/S ratio were significantly higher (p <0.002) The incidence of sudden cardiac death (SCD) increases with age in parallel with coronary's diseases' prevalence. In young persons and athletes, SCD occurs in half of the cases, in the setting of genetically transmitted disorders such as cardiomyopathies. Molecular testing performed after necropsy may help management of families but experience in this area appears very limited. The aim is to report our experience of post mortem molecular testing after SCD and necropsy. We studied 36 patients <40 years who died suddenly with a suspected diagnosis of cardiomyopathy, established either after autopsy or known before death , with 6 dilated cardiomyopathy (DCM), 12 hypertrophic (HCM), 2 HCM/DCM , 1 restrictive (CMR), 14 arrhythmogenic right ventricular cardiomyopathy (ARVC), 1 HMC and left ventricular noncompaction. Sanger sequencing was performed in most 4-5 frequent genes for a given phenotype. Fifteen mutations have been identified in sarcomeric (11 mutations) or desmosomal (3 mutations) or lamin (1 mutation) genes. The identification of these mutations had significant impact: assessing right diagnosis in a doubtful case (HCM without LVH), modifying the appropriate diagnosis in another case (HCM and not DCM), confirming a genetic disease even in the absence of affected relatives in the family, providing guidance for genetic counselling and predictive genetic testing in relatives in all situations. Technical, ethical and legal issues may however be encountered and will be discussed. This study is one of rare series of post-mortem molecular testing after SCD. Our findings suggest the feasibility, molecular efficiency and the clinical benefit of the approach in order to improve the management of families. Postmortem molecular testing must take its place in the strategy of family care after SCD, even if a cardiomyopathy is suspected at necropsy, since genetic findings provide additional information useful for the relatives.
Features and outcomes of acute myocarditis in children
Camille Walton, Magali Veyrier, Corinne Ducreux, Mohamed Bakloul, François Sassolas, Loic Boussel, Olivier Desebbe, Roland Henaine, Olivier Metton, Jean Ninet, Sylvie Di Filippo Hôpital Cardiovasculaire, Cardiologie pédiatrique et congénitale, Lyon, France This study was to assess features and outcomes of children with acute myocarditis.
Methods: Patients <18y with acute myocarditis (proved by virology and/ or MRI and/ or complete recovery of myocardial function) were included. Clinical data, echocardiographic parameters and outcomes were collected and cases divided in groups I (< 2y), II (2 to 10y) and III (>10y).
Results: 72 patients were included (1983 to 2012), 30males, aged 4.1±5.1y (med1.5y): 43 in group I, 17 in II and 12 in III. Heart failure was present at onset in 57(78%): 8 cardiogenic shock (12%), 30 severeHF (44%) were more frequent in I (56%) and II (46%) than in III (17%, p< 0.0001), chest pain (15.5%) was more frequent in III (83%). LVSF at diagnosis was 18.4±9%: 16% and 15% in groups I and II vs 30.5% in III (p= 0.0001). Aortic VTI was 11.4±5.8cm: 8cm and 11 in groups I and II vs 17 in group III (p< 0.05). Mitral regurgitation was present in 76.5%, pericarditis in 16.4%, thromboembolic events occurred in 5(7%), arrhythmias in 7(10%). Virus was found in 27=37.5% (1virus in 24, >in 3). Nine patients died (13%) within 2months post-diagnosis (2days to 8.6months), 1 was transplanted (3rdmonth), 19 have sequellae (27.5%), 40 recovered (58%), at FU= 5.5±5.6y. Inotrope was needed in 34(47%):51%, 59% and 16% of groups I, II and III respectively (p<0.0001). Six (8.3%, 1 in groupIII) needed mechanical circulatory support (3ECMO, 3VAD), within day-14 from onset: 1 died on support, 5 were
